Ertugliflozin plus sitagliptin more effective than monotherapy with either | ADA

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Ertugliflozin plus sitagliptin is more effective than either treatment alone for the reduction of HbA1c and fasting plasma glucose (FPG). 

Why this matters

  • Ertugliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor in development for the treatment of type 2 diabetes. (T2D). 

Study design

  • Researchers with the VERTIS FACTORIAL Trial extension conducted this double-blind phase 3 trial, in which 1233 participants with HbA1c 7.5%-11.0% on stable metformin monotherapy ≥1500 mg/d were randomized into five groups.
  • Ertugliflozin plus sitagliptin combinations were compared with corresponding ertugliflozin doses (5 mg or 15 mg) or sitagliptin alone.
  • The primary outcome was at wk 26; treatment was continued in a...